We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
Read MoreHide Full Article
Key Takeaways
J&J's oncology sales rose 20.6% to $18.52B, fueled by Darzalex, Erleada and new cancer drugs.
ImmunityBio's Anktiva gained U.S. approval for NMIBC, with $74.7M in 2025 sales.
Foghorn Therapeutics is advancing FHD-909 for SMARCA4-mutant cancers.
An updated edition of the October 28, 2025, article.
The global oncology market is entering a period of significant evolution, supported by rising cancer incidence and rapid scientific advancement. The American Cancer Society estimates that the United States will record approximately 2.04 million new cancer diagnoses and more than 618,000 cancer-related deaths in 2025. Globally, aging populations and lifestyle-related risk factors are contributing to higher cancer prevalence, prompting sustained growth in healthcare spending on oncology.
At the same time, innovation is reshaping cancer care. Breakthroughs in immunotherapies, targeted treatments and personalized vaccines have broadened therapeutic options well beyond conventional chemotherapy and radiation. Immune-based strategies — including checkpoint inhibitors, CAR-T therapies, therapeutic vaccines and oncolytic viruses — harness the body’s immune system to target tumors. Targeted therapies improve treatment precision by focusing on specific genetic alterations, while personalized cancer vaccines mark a meaningful advance in precision oncology.
Emerging technologies such as genomic sequencing, artificial intelligence (AI) and machine learning (ML) are accelerating biomarker discovery, enhancing patient stratification and supporting earlier diagnosis. While a universal cure remains out of reach, improvements in survival rates and quality of life across several cancer types underscore the impact of scientific progress and earlier intervention.
Pharmaceutical companies are responding with aggressive investment. Global leaders —including Novartis, AstraZeneca, J&J (JNJ - Free Report) , Pfizer (PFE - Free Report) , AbbVie (ABBV - Free Report) , Merck (MRK - Free Report) , Bristol Myers Squibb and Eli Lilly (LLY - Free Report) — are strengthening their oncology portfolios with antibody-drug conjugates (ADCs), bispecific antibodies and next-generation immuno-oncology therapies. Smaller biotech firms continue to play a critical role in innovation, driving partnerships, licensing agreements and acquisitions as larger players seek differentiated and high-potential assets.
Supported by ongoing innovation, favorable reimbursement dynamics and a growing range of treatment options, oncology remains one of the most durable and attractive segments within the global healthcare sector for long-term investors.
With our thematic screens, you can easily spot stocks tied to trends shaping the future of investing. If the cancerspace appeals to you and you’re looking to align your portfolio with this rising trend, now might be the time to consider stocks like J&J, ImmunityBio (IBRX - Free Report) , and Foghorn Therapeutics (FHTX - Free Report) .
J&J is one of the key pharmaceutical players in the oncology segment with significant expertise in blood cancers and solid tumors.
Its Oncology segment, at present, comprises around 27% of its total revenues. Its oncology sales rose 20.6% on an operational basis in the first nine months to $18.52 billion, driven by strong market growth and share gains of key products such as multiple myeloma treatment Darzalex and prostate cancer drug, Erleada. New cancer drugs, such as Carvykti, Tecvayli, Talvey and Rybrevant, plus Lazcluze, contributed significantly to growth as they witnessed strong launches.
Meanwhile, J&J’s oncology pipeline has gained strong momentum in the last couple of years with promising developments in colorectal and head and neck cancers. In this period, J&J had eight proof-of-concept readouts, which led the candidates to move to late-stage pivotal studies across the portfolio. If these pipeline drugs are eventually approved, they can also boost JNJ’s oncology sales.
J&J is also building its oncology pipeline through M&A deals. Last month, it announced a definitive agreement to acquire Halda Therapeutics, which will strengthen its oncology pipeline, mainly in prostate cancer, where it already has a strong presence with drugs like Zytiga, Erleada and Akeega.
J&J expects its oncology sales to reach $50 billion by the end of the decade.
ImmunityBio’s lead drug, Anktiva, was approved in April 2024 in combination with Bacillus Calmette-Guérin (BCG) to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) in the United States. Anktiva, a first-in-class IL-15 agonist IgG1 fusion complex, is witnessing strong demand trends and has generated $74.7 million in year-to-date sales, with volumes rising 467%.
The drug is under review in the EU. Last week, the European Medicines Agency recommended granting a conditional marketing authorization in the EU for Anktiva for treating NMIBC that does not respond to BCG.
ImmunityBio is simultaneously evaluating Anktiva, either as a monotherapy or in combination with other agents, for expanded use in bladder cancer as well as for other cancer indications like NSCLC, glioblastoma and non-Hodgkin lymphoma. In NSCLC studies, it has shown potential to reverse lymphopenia and extend overall survival, while in glioblastoma studies, it showed strong data in achieving disease control. ImmunityBio has a Zacks Rank #2.
Leveraging its proprietary Gene Traffic Control platform, Foghorn Therapeutics is developing new precision therapies that address genetically driven vulnerabilities within the chromatin regulatory system.
It has a collaboration with Lilly to co-develop and co-commercialize its selective SMARCA2 oncology program and an additional undisclosed oncology target. In collaboration with Lilly, Foghorn’s lead candidate FHD-909, a first-in-class SMARCA2 inhibitor, is advancing in a phase I dose escalation study for the treatment of SMARCA4-mutated cancers with a focus on NSCLC. Initial data from the study is expected in 2026. FHD-909 has shown significant anti-tumor activity across multiple SMARCA4-mutant lung tumor models. There is a significant unmet need for treating SMARCA4 mutant NSCLC patients.
Foghorn’s pre-clinical pipeline includes wholly-owned, first-in-class selective degrader programs targeting CBP, EP300 and ARID1B genes. Foghorn has a Zacks Rank of 2.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
Key Takeaways
An updated edition of the October 28, 2025, article.
The global oncology market is entering a period of significant evolution, supported by rising cancer incidence and rapid scientific advancement. The American Cancer Society estimates that the United States will record approximately 2.04 million new cancer diagnoses and more than 618,000 cancer-related deaths in 2025. Globally, aging populations and lifestyle-related risk factors are contributing to higher cancer prevalence, prompting sustained growth in healthcare spending on oncology.
At the same time, innovation is reshaping cancer care. Breakthroughs in immunotherapies, targeted treatments and personalized vaccines have broadened therapeutic options well beyond conventional chemotherapy and radiation. Immune-based strategies — including checkpoint inhibitors, CAR-T therapies, therapeutic vaccines and oncolytic viruses — harness the body’s immune system to target tumors. Targeted therapies improve treatment precision by focusing on specific genetic alterations, while personalized cancer vaccines mark a meaningful advance in precision oncology.
Emerging technologies such as genomic sequencing, artificial intelligence (AI) and machine learning (ML) are accelerating biomarker discovery, enhancing patient stratification and supporting earlier diagnosis. While a universal cure remains out of reach, improvements in survival rates and quality of life across several cancer types underscore the impact of scientific progress and earlier intervention.
Pharmaceutical companies are responding with aggressive investment. Global leaders —including Novartis, AstraZeneca, J&J (JNJ - Free Report) , Pfizer (PFE - Free Report) , AbbVie (ABBV - Free Report) , Merck (MRK - Free Report) , Bristol Myers Squibb and Eli Lilly (LLY - Free Report) — are strengthening their oncology portfolios with antibody-drug conjugates (ADCs), bispecific antibodies and next-generation immuno-oncology therapies. Smaller biotech firms continue to play a critical role in innovation, driving partnerships, licensing agreements and acquisitions as larger players seek differentiated and high-potential assets.
Supported by ongoing innovation, favorable reimbursement dynamics and a growing range of treatment options, oncology remains one of the most durable and attractive segments within the global healthcare sector for long-term investors.
With our thematic screens, you can easily spot stocks tied to trends shaping the future of investing. If the cancerspace appeals to you and you’re looking to align your portfolio with this rising trend, now might be the time to consider stocks like J&J, ImmunityBio (IBRX - Free Report) , and Foghorn Therapeutics (FHTX - Free Report) .
Explore 36 cutting-edge investment themes with Zacks Thematic Investing Screens and uncover your next big opportunity.
3 Cancer Stocks in Focus
J&J is one of the key pharmaceutical players in the oncology segment with significant expertise in blood cancers and solid tumors.
Its Oncology segment, at present, comprises around 27% of its total revenues. Its oncology sales rose 20.6% on an operational basis in the first nine months to $18.52 billion, driven by strong market growth and share gains of key products such as multiple myeloma treatment Darzalex and prostate cancer drug, Erleada. New cancer drugs, such as Carvykti, Tecvayli, Talvey and Rybrevant, plus Lazcluze, contributed significantly to growth as they witnessed strong launches.
Meanwhile, J&J’s oncology pipeline has gained strong momentum in the last couple of years with promising developments in colorectal and head and neck cancers. In this period, J&J had eight proof-of-concept readouts, which led the candidates to move to late-stage pivotal studies across the portfolio. If these pipeline drugs are eventually approved, they can also boost JNJ’s oncology sales.
J&J is also building its oncology pipeline through M&A deals. Last month, it announced a definitive agreement to acquire Halda Therapeutics, which will strengthen its oncology pipeline, mainly in prostate cancer, where it already has a strong presence with drugs like Zytiga, Erleada and Akeega.
J&J expects its oncology sales to reach $50 billion by the end of the decade.
J&J has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ImmunityBio’s lead drug, Anktiva, was approved in April 2024 in combination with Bacillus Calmette-Guérin (BCG) to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) in the United States. Anktiva, a first-in-class IL-15 agonist IgG1 fusion complex, is witnessing strong demand trends and has generated $74.7 million in year-to-date sales, with volumes rising 467%.
The drug is under review in the EU. Last week, the European Medicines Agency recommended granting a conditional marketing authorization in the EU for Anktiva for treating NMIBC that does not respond to BCG.
ImmunityBio is simultaneously evaluating Anktiva, either as a monotherapy or in combination with other agents, for expanded use in bladder cancer as well as for other cancer indications like NSCLC, glioblastoma and non-Hodgkin lymphoma. In NSCLC studies, it has shown potential to reverse lymphopenia and extend overall survival, while in glioblastoma studies, it showed strong data in achieving disease control. ImmunityBio has a Zacks Rank #2.
Leveraging its proprietary Gene Traffic Control platform, Foghorn Therapeutics is developing new precision therapies that address genetically driven vulnerabilities within the chromatin regulatory system.
It has a collaboration with Lilly to co-develop and co-commercialize its selective SMARCA2 oncology program and an additional undisclosed oncology target. In collaboration with Lilly, Foghorn’s lead candidate FHD-909, a first-in-class SMARCA2 inhibitor, is advancing in a phase I dose escalation study for the treatment of SMARCA4-mutated cancers with a focus on NSCLC. Initial data from the study is expected in 2026. FHD-909 has shown significant anti-tumor activity across multiple SMARCA4-mutant lung tumor models. There is a significant unmet need for treating SMARCA4 mutant NSCLC patients.
Foghorn’s pre-clinical pipeline includes wholly-owned, first-in-class selective degrader programs targeting CBP, EP300 and ARID1B genes. Foghorn has a Zacks Rank of 2.